Antony, France, 8 March 2013 – Stallergenes S.A. (Euronext Paris CAC small) plans to evaluate
possible cooperation with Greer Laboratories, Inc. for the US distribution of Oralair, its 5-grass pollen
extract allergen immunotherapy (AIT) sublingual tablet. Stallergenes will judge this opportunity on its
own merit, regardless of Ares Life Sciences’ announcement of the signing of a definitive agreement to
acquire Greer Laboratories, Inc..
On 18 February 2013, Stallergenes announced that the FDA had agreed to review its Biologics
License Application (BLA) for Oralair.